Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013933 · ClinicalTrials.gov registry record · Phase 1
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03013933 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT03013933, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of brentuximab vedotin and cyclosporine when given together with verapamil hydrochloride in treating patients with Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunosuppressive therapies, such as cyclosporine, may improve bone marrow function and increase blood cell counts. Verapamil hydrochloride may increase the effectiveness of brentuximab vedotin by overcoming drug resistance of the cancer cells. Giving brentuximab vedotin, cyclosporine, and verapamil hydrochloride may work better in treating patients with Hodgkin lymphoma.
Interventions
- DRUG Brentuximab Vedotin
- DRUG Cyclosporine
- OTHER Pharmacokinetic Study
- DRUG Verapamil
- DRUG Verapamil Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-05-03 |
| Est. Completion | 2022-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03013933
The ClinicalTrials.gov registry entry for NCT03013933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Brentuximab Vedotin is the first listed.
NCT03013933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03013933 about?
NCT03013933 is a clinical study titled "Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma". This phase I trial studies the side effects and best dose of brentuximab vedotin and cyclosporine when given together with verapamil hydrochloride in treating patients with Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclon...
What is the current status of trial NCT03013933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-05-03. Estimated completion is 2022-05-24.
What interventions are being tested in trial NCT03013933?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Cyclosporine (DRUG), Pharmacokinetic Study (OTHER), Verapamil (DRUG), Verapamil Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03013933?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.